|
SK55593A3
(en)
|
1991-03-05 |
1993-10-06 |
Wellcome Found |
Expresion of recombinant proteins in attenuated bacteria
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
DK0897983T3
(da)
|
1991-10-25 |
2003-08-11 |
Immunex Corp |
Antistoffer mod CD40-L
|
|
GB9202219D0
(en)
*
|
1992-02-03 |
1992-03-18 |
Connaught Lab |
A synthetic heamophilus influenzae conjugate vaccine
|
|
EP0659086B1
(en)
|
1992-09-04 |
1998-11-11 |
The University of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
GB9420146D0
(en)
*
|
1994-10-06 |
1994-11-23 |
Cancer Res Campaign Tech |
Papillomavirus vaccine
|
|
PT812206E
(pt)
|
1995-03-01 |
2002-11-29 |
Immunex Corp |
Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
|
|
NZ311335A
(en)
|
1995-06-07 |
1998-05-27 |
Immunex Corp |
Cd40l muteins and their use as ligands
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
EP1059932A1
(en)
|
1997-12-19 |
2000-12-20 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
ATE403728T1
(de)
|
1998-09-04 |
2008-08-15 |
Emergent Product Dev Uk Ltd |
Attenuierte salmonella spi2 mutante als antigen- träger
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
IL144952A0
(en)
|
1999-04-16 |
2002-06-30 |
Hoffmann La Roche |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
WO2001013948A1
(en)
*
|
1999-08-20 |
2001-03-01 |
The General Hospital Corporation |
Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
|
|
US7118751B1
(en)
|
1999-10-14 |
2006-10-10 |
Trubion Pharmaceuticals, Inc. |
DNA vaccines encoding antigen linked to a domain that binds CD40
|
|
DK1112747T3
(da)
|
1999-12-28 |
2004-10-25 |
Akzo Nobel Nv |
Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
|
|
WO2001054472A2
(en)
|
2000-01-31 |
2001-08-02 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
EP1255560B1
(en)
|
2000-02-02 |
2008-10-29 |
UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE |
Cd40 ligand adjuvant for respiratory syncytial virus vaccine
|
|
BR0109322A
(pt)
|
2000-03-17 |
2002-12-10 |
Upjohn Co |
Materiais e métodos de vacina de salmonella
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
WO2002000232A2
(en)
|
2000-06-26 |
2002-01-03 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
ATE438710T1
(de)
|
2001-05-15 |
2009-08-15 |
Ortho Mcneil Janssen Pharm |
Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
BR0209689A
(pt)
|
2001-05-15 |
2006-02-07 |
Long Island Jewish Res Inst |
Uso de fragmento de hmg como agente anti-inflamatório
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
ATE395602T1
(de)
|
2001-12-19 |
2008-05-15 |
Alcedo Biotech Gmbh |
Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
|
|
AU2002359780B2
(en)
|
2001-12-21 |
2009-08-13 |
Immunex Corporation |
Recombinant polypeptides
|
|
ATE421249T1
(de)
|
2002-02-13 |
2009-02-15 |
Immunology Lab Inc |
Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP2380440B1
(en)
|
2002-04-15 |
2016-03-09 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
JP2006510619A
(ja)
|
2002-11-20 |
2006-03-30 |
クリティカル セラピューティクス，インコーポレイテッド |
抗炎症剤としてのｈｍｇｂ断片の使用
|
|
WO2004046338A2
(en)
|
2002-11-20 |
2004-06-03 |
North Shore-Long Island Jewish Research Institute |
Use of hmgb polypeptides for increasing immune responses
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
EP1673389A2
(en)
|
2003-10-10 |
2006-06-28 |
Xencor Inc. |
Novel variants of cd40l protein
|
|
ES2358804T3
(es)
|
2003-11-21 |
2011-05-13 |
Ace Biosciences A/S |
Polipéptidos de campylobacter jejuni ubicados en superficie.
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
CA2548347A1
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
EP1740604A2
(en)
|
2004-04-27 |
2007-01-10 |
Intercell AG |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
US20080305120A1
(en)
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
DE602005025005D1
(de)
|
2004-10-07 |
2011-01-05 |
Argos Therapeutics Inc |
Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
US20060286074A1
(en)
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
WO2007011606A2
(en)
|
2005-07-18 |
2007-01-25 |
Critical Therapeutics, Inc. |
USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
|
|
PT1949913E
(pt)
|
2005-10-07 |
2010-08-24 |
Proyecto Biomedicina Cima Sl |
Associação imunoestimuladora para a profilaxia e o tratamento da hepatite c
|
|
AU2006311752A1
(en)
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
WO2007130725A2
(en)
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
|
CU23576A1
(es)
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007106073A2
(en)
|
2006-03-02 |
2007-09-20 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
CN101064542B
(zh)
|
2006-04-30 |
2010-12-08 |
中兴通讯股份有限公司 |
Mimo ofdm系统中发射天线选择与自适应调制方法
|
|
WO2008017517A1
(en)
*
|
2006-08-11 |
2008-02-14 |
Life Sciences Research Partners Vzw |
Immunogenic peptides and their use in immune disorders
|
|
EP2586790A3
(en)
*
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
EP2517723B1
(en)
|
2006-09-18 |
2019-11-06 |
The Board of Trustees of The University of Arkansas |
Compositions and methods of enhancing immune responses
|
|
US20100292309A1
(en)
|
2007-03-08 |
2010-11-18 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
BRPI0818736A2
(pt)
|
2007-10-30 |
2017-06-13 |
Univ Arkansas |
composições e métodos para intensificar imunorrepostas à bactéria flagelada
|
|
WO2009059298A2
(en)
|
2007-11-01 |
2009-05-07 |
Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancinc immune responses to eimeria
|
|
JP2012530500A
(ja)
*
|
2009-06-26 |
2012-12-06 |
ヴェクトライト バイオメディカ インコーポレイテッド |
サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法
|
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
|
CN102811734B
(zh)
|
2010-01-21 |
2016-02-10 |
阿肯色大学评议会 |
增强免疫应答的疫苗载体和方法
|
|
WO2013071298A1
(en)
|
2011-11-11 |
2013-05-16 |
Nutrition Physiology Company, Llc |
Lactic acid bacteria and their use as dietary supplementals for poultry
|
|
CA2800830C
(en)
|
2010-06-09 |
2020-09-08 |
The Board Of Trustees Of The University Of Arkansas |
Vaccine and methods to reduce campylobacter infection
|
|
CN104159601B
(zh)
|
2012-02-01 |
2017-05-24 |
代表亚利桑那大学的亚利桑那董事会 |
弯曲杆菌属免疫原性组合物及其用途
|
|
WO2014028776A1
(en)
|
2012-08-15 |
2014-02-20 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
EA031234B1
(ru)
|
2012-10-29 |
2018-12-28 |
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас |
Вакцина с адъювантом на основе маннозилированного хитозана
|
|
HUE047484T2
(hu)
|
2013-02-14 |
2020-04-28 |
Univ Arkansas |
Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
|
|
US10376571B2
(en)
*
|
2013-03-15 |
2019-08-13 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to enteric pathogens
|